Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Skinmed ; 17(1): 68-71, 2019.
Article in English | MEDLINE | ID: mdl-30888954

ABSTRACT

A 47-year-old white woman presented to our clinic complaining of recalcitrant warts on her trunk and extremities. She had an extensive past medical history including immunodeficiency of unknown origin, pulmonary hypertension, rheumatoid arthritis, and systemic lupus erythematosus, for which she was being treated with chronic immunosuppressive therapy with methylprednisolone and belimumab. The patient had previously failed treatments at an outside facility with liquid nitrogen, trichloroacetic acid, topical cidofovir, imiquimod, topical 5-fluorouracil, intralesional candida antigen, pulsed-dye laser (Vbeam Perfecta), surgical excision, and photodynamic therapy. (SKINmed. 2019;17:68-71).


Subject(s)
Hyperthermia, Induced/methods , Warts/therapy , Combined Modality Therapy , Female , Humans , Middle Aged , Treatment Outcome , Warts/pathology
2.
J Neurooncol ; 140(2): 341-349, 2018 Nov.
Article in English | MEDLINE | ID: mdl-30132164

ABSTRACT

PURPOSE/OBJECTIVE(S): To compare the performance of five prognostic models [RTOG recursive partitioning analysis (RPA), Score Index for Radiosurgery in Brain Metastases (SIR), Barnholtz-Sloan-Kattan nomogram (BSKN), diagnosis-specific Graded Prognostic Assessment (dsGPA), and Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA)] against actual survival in patients with brain metastases treated with SRS +/- WBRT. MATERIALS/METHODS: 100 consecutive patients treated with SRS +/- WBRT between January 2006 and July 2012 were retrospectively analyzed. Patients were binned according to 33 percentiles of the predicted survival distribution for the BSKN and dsGPA models to compare with LungmolGPA, RPA and SIR. Pearson's correlation coefficients between predicted and observed survival were estimated to quantify the proportion of variance in observed survival. RESULTS: Median survival for the entire cohort was 13.5 months, with predicted vs actual MS by BSKN, SIR, dsGPA, RPA, adenocarcinoma Lung-molGPA, and nonadenocarcinoma Lung-molGPA was 3.8 vs 15.6 months, 7 vs 13.5 months, 9.4 vs 13.5 months, 10.3 vs 13.5 months, 13.7 vs 13.7 months, and 9.8 vs 9.7 months, respectively. The BSKN model and adenocarcinoma LungmolGPA created three groups with a statistically significantly different MS (p = 0.002 and p = 0.01, respectively). CONCLUSION: All models under-predicted MS and only the BSKN and Lung-molGPA model stratified patients into three risk groups with statistically significant actual MS. The prognostic groupings of the adenocarcinoma Lung-molGPA group was the best predictor of MS, and showed that we are making improvements in our prognostic ability by utilizing molecular information that is much more widely available in the current treatment era.


Subject(s)
Brain Neoplasms/diagnosis , Brain Neoplasms/radiotherapy , Cranial Irradiation , Radiosurgery , Adult , Aged , Aged, 80 and over , Brain Neoplasms/mortality , Brain Neoplasms/secondary , Female , Humans , Male , Middle Aged , Models, Biological , Prognosis , Retrospective Studies , Survival Analysis
3.
Pract Radiat Oncol ; 7(5): e299-e308, 2017.
Article in English | MEDLINE | ID: mdl-28214145

ABSTRACT

PURPOSE: Reduction mammoplasty (RM) during breast-conserving surgery is popular among women with large-volume breasts because it reduces redundant breast folds and may decrease skin-related morbidity from radiation therapy. However, RM may obscure the lumpectomy cavity (LC) and pose challenges to administering an LC boost, potentially affecting local control. We investigated the impact of RM on acute side effects and use of LC boosts. METHODS AND MATERIALS: The records of 645 consecutive women treated with whole-breast irradiation at an urban university and 2 community practices between January 2012 and December 2014 were reviewed on an institutional review board-approved study. The primary endpoint was grade ≥3 radiation dermatitis; the secondary endpoint was use of LC boost. Student 2-sample t tests, Pearson χ2 tests, Fisher exact tests, and univariate and multivariable logistic regression analyses were performed. RESULTS: Forty-three (7%) RMs were performed in 650 treated breasts. No significant differences in grade 3 toxicities were identified among RM and non-RM patients. LC boost was delivered to 474 breasts. Fewer (16/43) RM patients received LC boosts compared with non-RM patients (458/607), P = .0001. RM patients were more likely to have neoadjuvant chemotherapy, stage III or multifocal disease, higher body mass index, larger planning treatment volumes, and conventional fractionation (P < .05). CONCLUSIONS: RM was associated with decreased use of LC boost without significant differences in acute toxicities. Further investigation to delineate LCs in patients undergoing RM or identify alternative strategies for delivering LC dose is needed.


Subject(s)
Breast Neoplasms/therapy , Mammaplasty/adverse effects , Mastectomy, Segmental/adverse effects , Radiodermatitis/epidemiology , Acute Disease , Adult , Aged , Aged, 80 and over , Body Mass Index , Breast/diagnostic imaging , Breast/radiation effects , Breast/surgery , Breast Neoplasms/pathology , Dose Fractionation, Radiation , Female , Humans , Mammaplasty/methods , Mastectomy, Segmental/methods , Middle Aged , Neoadjuvant Therapy , Neoplasm Staging , Radiodermatitis/etiology , Radiodermatitis/prevention & control , Radiotherapy, Adjuvant/adverse effects , Radiotherapy, Adjuvant/methods , Tomography, X-Ray Computed
4.
J Radiat Oncol ; 2(2): 203-208, 2013 Jun 01.
Article in English | MEDLINE | ID: mdl-23828730

ABSTRACT

OBJECTIVE: We examined the relative response to radiation of the upper lung lobes (UL) versus lower lung lobes (LL) of normal lung tissue using normalized [18F]-fluorodeoxyglucose (FDG) uptake per radiation dose received per lung voxel in patients treated with either photons or protons and tested for correlation of the radiation response with clinical pneumonitis. METHODS: Seventy-five patients (photon (n = 51) or proton (n = 24)) treated for esophageal cancer from November 1, 2003 to May 15, 2011 who received restaging FDG-positron emission tomography (PET) imaging 1 to 3 months after chemoradiation were selected. UL and LL were contoured using the major fissure as the boundary, with the right middle lobe being included in the right UL structure. Pneumonitis toxicity was scored using the Common Terminology Criteria for Adverse Events, version 4.0 based on the consensus of 5 clinicians. RESULTS: LL had a higher mean dose (15.6 Gy vs. 10.4 Gy, p<0.001), higher mean standard uptake value (SUV) (0.78 vs. 0.56, p=0.001) and SUV in low dose regions (0.80 vs. 0.66 for 10 to 20 Gy, p=0.001), and lower mean dose response (0.015 vs. 0.019, p=0.003) compared to the UL. The mean dose ratio of UL vs. LL (p < 0.001), and SUV in the region of lung receiving 0-10 Gy (p=0.04), but not the dose response ratio of UL vs. LL (p=0.53) correlated with symptomatic pneumonitis. CONCLUSION: Upper lung lobes had a greater pulmonary metabolic radiation response than lower lung lobes. Greater dose to UL relative to LL and higher SUV in the low dose region (10-20 Gy) on post-treatment PET correlated with symptomatic pneumonitis.

5.
Nucleic Acids Res ; 38(5): 1623-35, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20008101

ABSTRACT

Oligodeoxynucleotide libraries containing randomly incorporated bases are used to generate DNA aptamers by systematic evolution of ligands by exponential enrichment (SELEX). We predicted that combinatorial libraries with alternative base compositions might have innate properties different from the standard library containing equimolar A + C + G + T bases. In particular, we hypothesized that G-rich libraries would contain a higher proportion of quadruplex-forming sequences, which may impart desirable qualities, such as increased nuclease resistance and enhanced cellular uptake. Here, we report on 11 synthetic oligodeoxynucleotide libraries of various base combinations and lengths, with regard to their circular dichroism, stability in serum-containing medium, cellular uptake, protein binding and antiproliferative activity. Unexpectedly, we found that some G-rich libraries (composed of G + T or G + C nucleotides) strongly inhibited cancer cell growth while sparing non-malignant cells. These libraries had spectral features consistent with G-quadruplex formation, were significantly more stable in serum than inactive libraries and showed enhanced cellular uptake. Active libraries generally had strong protein binding, while the pattern of protein binding suggested that G/T and G/C libraries have distinct mechanisms of action. In conclusion, cancer-selective antiproliferative activity may be a general feature of certain G-rich oligodeoxynucleotides and is associated with quadruplex formation, nuclease resistance, efficient cellular uptake and protein binding.


Subject(s)
Antineoplastic Agents/chemistry , Aptamers, Nucleotide/chemistry , Guanine/analysis , Oligodeoxyribonucleotides/chemistry , Antineoplastic Agents/metabolism , Antineoplastic Agents/pharmacology , Aptamers, Nucleotide/pharmacology , Base Composition , Cell Line , Cell Line, Tumor , Cell Proliferation/drug effects , Circular Dichroism , Flow Cytometry , G-Quadruplexes , Gene Library , Humans , Oligodeoxyribonucleotides/metabolism , Oligodeoxyribonucleotides/pharmacology , Proteins/metabolism , SELEX Aptamer Technique
6.
Methods Mol Biol ; 542: 379-92, 2009.
Article in English | MEDLINE | ID: mdl-19565914

ABSTRACT

Oligonucleotides with guanosine-rich (G-rich) sequences often have unusual physical and biological properties, including resistance to nucleases, enhanced cellular uptake, and high affinity for particular proteins. Furthermore, we have found that certain G-rich oligonucleotides (GROs) have antiproliferative activity against a range of cancer cells, while having minimal toxic effects on normal cells. We have investigated the mechanism of this activity and studied the relationship between oligonucleotide structural features and biological activity. Our results indicate that the antiproliferative effects of GROs depend on two properties: the ability to form quadruplex structures stabilized by G-quartets and binding affinity for nucleolin protein. Thus, it appears that the antiproliferative GROs are acting as nucleolin aptamers. Because nucleolin is expressed at high levels on the surface of cancer cells, where it mediates the endocytosis of various ligands, it seems likely that nucleolin-dependent uptake of GROs plays a role in their activity. One of the GROs that we have developed, a 26-nucleotide phosphodiester oligodeoxynucleotide now named AS1411 (formerly AGRO100 or GRO26B-OH), is currently being tested as an anticancer agent in Phase II clinical trials.


Subject(s)
Guanosine/metabolism , Molecular Biology/methods , Neoplasms/therapy , Oligonucleotides/pharmacology , Cell Survival/drug effects , Circular Dichroism , Deoxyribonucleases/metabolism , Electrophoretic Mobility Shift Assay , HeLa Cells , Humans , Nucleic Acid Denaturation/drug effects , Nucleic Acid Renaturation/drug effects , Oligonucleotides/analysis , Radioisotopes , Staining and Labeling , Sterilization
7.
Cancer Res ; 65(9): 3823-7, 2005 May 01.
Article in English | MEDLINE | ID: mdl-15867380

ABSTRACT

Dog and rat animal models have been developed for repeated intravascular administrations to the liver. However, mice have generally been considered too small to use for these models. This study describes the development of mouse models that permit the establishment of liver metastases that can be subsequently treated by repeated injections into the portal venous system. A mini-laparotomy is done to mobilize the spleen and transpose it to a s.c. pocket with its vascular pedicle intact. A suspension of single tumor cells is then inoculated into the portal vein to establish diffuse liver metastases. These tumors may be treated by simple percutaneous injections directly into the s.c. whole spleen reservoir. The ease of injection into the s.c. spleen permits repeated injections into the portal venous system. The usefulness of this model was shown in experiments revealing that multiple portal venous administrations of a replication-conditional, oncolytic herpes simplex virus mutant are more effective than a single portal venous administration. In a modification of this model, the spleen is first split into two, leaving intact the vascular pedicle for each half of the spleen. Tumor cells are inoculated into one hemi-spleen, which is then resected 10 minutes later. The other hemi-spleen is transposed to the s.c. position, thereby permitting subsequent repetitive portal venous injections via percutaneous injections into the s.c. hemi-spleen. These mouse models are useful for a wide range of studies.


Subject(s)
Drug Delivery Systems/methods , Liver Neoplasms, Experimental/secondary , Liver Neoplasms, Experimental/virology , Liver/blood supply , Simplexvirus/physiology , Spleen/blood supply , Spleen/surgery , Animals , Chlorocebus aethiops , Disease Models, Animal , Injections, Intravenous , Liver Neoplasms, Experimental/blood supply , Liver Neoplasms, Experimental/drug therapy , Mice , Mice, Inbred BALB C , Mice, Nude , Neoplasm Transplantation/methods , Portal Vein , Spleen/pathology , Vero Cells
8.
Cancer Res ; 64(7): 2561-7, 2004 Apr 01.
Article in English | MEDLINE | ID: mdl-15059912

ABSTRACT

Replication-conditional viruses destroy tumors in a process referred to as viral oncolysis. An important prerequisite for this cancer therapy strategy is use of viruses that replicate preferentially in neoplastic cells. In this study the DF3/MUC1 promoter/enhancer sequence is used to regulate expression of gamma(1)34.5 to drive replication of a Herpes simplex virus 1 (HSV-1) mutant (DF3gamma34.5) preferentially in DF3/MUC1-positive cells. HSV-1 gamma(1)34.5 functions to dephosphorylate elongation initiation factor 2alpha, which is an important step for robust HSV-1 replication. After DF3gamma34.5 infection of cells, elongation initiation factor 2alpha phosphatase activity and viral replication were observed preferentially in DF3/MUC1-positive cells but not in DF3/MUC1-negative cells. Regulation of gamma(1)34.5 function results in preferential replication in cancer cells that express DF3/MUC1, restricted biodistribution in vivo, and less toxicity as assessed by LD(50). Preferential replication of DF3gamma34.5 was observed in DF3/MUC1-positive liver tumors after intravascular perfusion of human liver specimens. DF3gamma34.5 was effective against carcinoma xenografts in nude mice. Regulation of gamma(1)34.5 by the DF3/MUC1 promoter is a promising strategy for development of HSV-1 mutants for viral oncolysis.


Subject(s)
Antigens, Neoplasm/genetics , Herpesvirus 1, Human/physiology , Melanoma/virology , Mucin-1/genetics , Animals , Antigens, Neoplasm/biosynthesis , Chlorocebus aethiops , Genetic Therapy/methods , Herpesvirus 1, Human/genetics , Melanoma/enzymology , Melanoma/metabolism , Melanoma/therapy , Mice , Mice, Inbred BALB C , Mice, Nude , Mucin-1/biosynthesis , Pancreatic Neoplasms/enzymology , Pancreatic Neoplasms/metabolism , Pancreatic Neoplasms/therapy , Pancreatic Neoplasms/virology , Phosphoprotein Phosphatases/metabolism , Promoter Regions, Genetic , Tissue Distribution , Vero Cells , Virus Replication , Xenograft Model Antitumor Assays
SELECTION OF CITATIONS
SEARCH DETAIL
...